NovaBay Pharmaceuticals to Present at the Roth Capital 23rd Annual Growth Stock Conference on March 16

By March 9, 2011

Ron Najafi, PhD, Chairman and Chief Executive Officer of NovaBay Pharmaceuticals (NYSE Amex: NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, will be presenting at Roth Capital Partners’ 23rd Annual Growth Stock Conference at The Ritz Carlton, Laguna Niguel in Dana Point, California. Dr. Najafi will be speaking in the Healthcare Track (Track 2) on Wednesday, March 16 at 1:30PM (PST).

Dr. Najafi will discuss the current status of NovaBay’s Aganocide® compounds, which are novel, broad-spectrum, fast-acting, antimicrobial molecules designed to mimic the body’s defense against infection. When applied topically, these compounds maintain biological activities while demonstrating improved solution stability over naturally occurring antimicrobial molecules. In clinical testing in 129 patients with impetigo infections, the lead Aganocide compounds have been shown to be highly effective against bacteria, including some multi-drug resistant strains such as MRSA with 92% clinical efficacy. In preclinical testing, Aganocide compounds have also shown good activity against viruses and fungi and have the potential to deliver the same or better efficacy than antibiotics. They also address the growing problem of antibiotic resistance by employing a novel mechanism of action.

The three-day Roth conference brings together executives from over 400 growth companies, including more than 135 leading biotechnology, pharmaceutical, medical devices/diagnostics and healthcare services companies. The event is designed to provide investors with a unique opportunity to gain insight into small and mid-cap growth companies across a variety of sectors, including energy, software, technology, industrials, healthcare, media, consumer and retail. The conference combines company presentations, Q&A sessions, expert panels and management one-on-one meetings to provide Roth’s institutional clients with extensive interaction with senior management to gain in-depth insights into each company.

To listen to a webcast of Dr. Najafi’s presentation, please visit the following link: presentation will be archived for 90 days.

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary and patented Aganocide compounds. These are novel, synthetic anti-infectives with activity against bacteria, fungi and viruses, and are being developed to treat and prevent a wide range of local, non-systemic infections with a low likelihood of developing bacterial resistance.

NovaBay is focusing its technology on four distinct therapeutic areas: dermatology, ophthalmology, urology and hospital infections. In dermatology, the focus is on developing NVC-422 gel for impetigo and acne. NovaBay has the distinct advantage of being partnered with Galderma, the leading dermatology company in the world. In ophthalmology, the goal is to develop an eye drop for conjunctivitis with Alcon, the world’s leading ophthalmology company. In urology, NovaBay aims to reduce the incidence of urinary catheter blockage and encrustation (UCBE) and the associated urinary tract infections with an irrigation solution containing NVC-422. In hospital infection, NovaBay is targeting the six-million-patient market of chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers with its proprietary antimicrobial solution, NeutroPhase®, which has received two 510K clearances from the Food and Drug Administration.

Cautionary Information Regarding Forward-Looking Statements
The statements in this press release regarding the potential efficacy of NovaBay’s Aganocide compounds and to address the growing problem of antibiotic resistance are forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. Factors that might cause to such differences include, but are not limited to: the risks that results obtained in animal models may not be obtained in humans; the risk that results obtained in pre-clinical studies may not be obtained in clinical studies, and inherent risks and uncertainties relating to difficulties or delays in conducting clinical trials, as well other as risks relating to NovaBay and its Aganocide compounds detailed in NovaBay’s Quarterly Report on Form 10-Q, under the caption “Risk Factors” in Item 1A of Part II of that report, which was filed with the Securities and Exchange Commission on November 12, 2010. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

NovaBay Pharmaceuticals Contacts
Thomas J. Paulson  
Chief Financial Officer
Contact Thomas Paulson

The Investor Relations Group
Investor Relations:
Adam Holdsworth

Public Relations:
Laura Colontrelle